Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Determine the Safety and Tolerability of Escalating Doses of Panobinostat (LBH589) in Patients With Sickle Cell Disease

NCT01245179 is registered in ClinicalTrials.gov with Abdullah Kutlar as lead sponsor.

NCT NCT01245179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01245179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Determine the Safety and Tolerability of Escalating Doses of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Lead sponsor
Abdullah Kutlar
Phase
Phase 1
Overall status
Recruiting
Start date
November 30, 2010
Completion date
January 31, 2027
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease